news
Merrimack initiates Phase 1 study of MM-310 in solid tumours
29 March 2017 | By Niamh Marriott, Junior Editor
Merrimack Pharmaceuticals have enrolled its first patient in a Phase 1 study of MM-310 in solid tumours.
List view / Grid view
Ovarian Cancer
news
Lynparza Phase III data demonstrates progression-free survival in ovarian cancer
17 March 2017 | By Niamh Marriott, Junior Editor
AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator assessed PFS (HR 0.30; 95%…
news
Phase III trial to evaluate avelumab as first-line treatment in ovarian cancer
6 July 2016 | By Victoria White, Digital Content Producer
Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer...
news
Aprea announces efficacy and safety data for APR-246 in ovarian cancer
7 June 2016 | By Victoria White, Digital Content Producer
Aprea presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial of APR-246 at the ASCO annual meeting...
news
NICE says ‘yes’ to two ovarian cancer drugs, rejects three
27 April 2016 | By Victoria White, Digital Content Producer
The guidance recommends paclitaxel and PLDH for treating ovarian cancer that has returned after previous chemotherapy treatment...
news
TPIV 200 and durvalumab to be evaluated in a Phase II ovarian cancer study
22 April 2016 | By Victoria White, Digital Content Producer
TapImmune plans to initiate a Phase II trial of TPIV 200 in combination with AstraZeneca’s durvalumab in patients with platinum-resistant ovarian cancer...
news
ImmunoGen and Merck collaborate for ovarian cancer trial
5 February 2016 | By Victoria White
The companies are to are to assess ImmunoGen’s mirvetuximab soravtansine in combination with Merck’s Keytruda (pembrolizumab) in FRα-positive ovarian cancer...
news
FDA grants Fast Track Designation to TapImmune’s TPIV 200
3 February 2016 | By Victoria White
The FDA has granted the designation for maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer...
article
FDA finally speeds up approval for ovarian cancer drugs
19 January 2016 | By Snehal Chougule, Allied Market Research
Snehal Chougule discusses the ovarian cancer treatment market and recent approvals by the US Food and Drug Administration...
news
Trial to investigate avelumab and entinostat in ovarian cancer
4 January 2016 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells...
news
Merck KGaA and Pfizer advance avelumab clinical development programme
22 December 2015 | By
Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer...
news
EMA grants Orphan Drug Designation for Debio 1143
8 December 2015 | By Victoria White
Debio1143 is an oral, small molecule inhibitor of IAPs with a dual pro-apoptotic and immunomodulatory mode of action developed as a potent chemo/radiosensitiser in ovarian cancer...
news
Aprea announces preliminary study data for APR-246 in ovarian cancer
26 October 2015 | By Victoria White
APR-246 combined with standard of care chemotherapy shows activity in the treatment of recurrent ovarian cancer...
news
HRT safe and perhaps beneficial in women treated for ovarian cancer
28 September 2015 | By Victoria White
A 24-year, Phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer can safely take HRT during or after their treatment.
news
NICE asks for more information on ovarian cancer drug olaparib
6 August 2015 | By Victoria White
NICE has opened a second consultation on preliminary draft guidance on olaparib for maintenance treatment of ovarian, fallopian tube and peritoneal cancer...
